- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 5/20 - Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
Patent holdings for IPC class A61P 5/20
Total number of patents in this class: 66
10-year publication summary
|
3
|
1
|
3
|
2
|
3
|
4
|
3
|
1
|
3
|
1
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Amgen Inc. | 4337 |
5 |
| Kai Pharmaceuticals, Inc. | 29 |
5 |
| Lupin Limited | 431 |
5 |
| Opko Ireland Global Holdings, Ltd. | 18 |
4 |
| Wisconsin Alumni Research Foundation | 3914 |
3 |
| Beijing Tuo Jie Biopharmaceutical Co., Ltd. | 33 |
3 |
| Chugai Seiyaku Kabushiki Kaisha | 1393 |
2 |
| Cytochroma Inc. | 16 |
2 |
| EA Pharma Co., Ltd. | 93 |
2 |
| Kyowa Hakko Kirin Co., Ltd. | 278 |
2 |
| Proventiv Therapeutics, LLC | 8 |
2 |
| Zhejiang Dtrm Biopharma Co. Ltd. | 16 |
2 |
| LEO Pharma A/S | 459 |
2 |
| The Regents of the University of California | 20506 |
1 |
| Ajinomoto Co., Inc. | 2281 |
1 |
| Abiogen Pharma S.p.A. | 154 |
1 |
| Asahi Kasei Pharma Corporation | 115 |
1 |
| Board of Trustees of the University of Arkansas | 823 |
1 |
| EirGen Pharma Limited | 88 |
1 |
| James Black Foundation Limited | 3 |
1 |
| Other owners | 20 |